LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in upcoming investor conferences.
William Blair 45th Annual Growth Stock Conference
Management to host investor meetings
Date: June 3, 2025
Location: Chicago, IL
Jefferies Global Healthcare Conference
Fireside Chat Presentation
Date and time: June 5, 2025; 3:10pm EDT / 20:10pm BST
Location: New York, NY
Presenter: Chief Executive Officer Dr. Christian Itin
Goldman Sachs 46th Annual Global Healthcare Conference
Fireside Chat Presentation
Date and time: June 11, 2025; 1:20pm EDT / 18:20 BST
Location: Miami, FL
Presenter: Chief Financial Officer Rob Dolski
A webcast of the fireside chats will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved and MHRA licensed product, obe-cel, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
This email address is being protected from spambots. You need JavaScript enabled to view it.
Olivia Manser
+44 7780 471 568
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.50 |
| Daily Change: | -0.07 -4.46 |
| Daily Volume: | 2,140,208 |
| Market Cap: | US$399.210M |
August 12, 2025 May 14, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
